Toll Free: 1-866-893-2424 scenar-usa@tds.net

The SCENAR device is heralded as an advanced form of electrotherapy in modern medical care for acute and chronic pain by using two physiological principles: that the body provides its own healing capabilities and continually employs the processes of self-regulation to maintain health. The Scenar device provides safe, non-invasive, systemic healing that is effective, easy to use, and universally acceptable to most everyone. It is a small hand-held device with a transdermal electroneuro-stimulator, graphic display (professional model), light emitting diodes (home use model) and audible indications. It delivers non-invasive, computer-modulated therapeutic electro stimulation via the client’s skin and includes high amplitude, short- duration waveforms with little to no discomfort. Extensive scientific studies have shown that working through the skin, the electrical pulses can have a profound effect on organs and tissues via the nerves of the body. When these pulses are similar to the natural neruo-pulses generated by the body, an excellent therapeutic effect is produced due to this devices high amplitude, allowing the small un-mylinated “C” fibers to be stimulated to a higher degree than other forms of electrotherapy. For example: when the C fibers are sufficiently stimulated they trigger neuro and regulative peptide release with results of pain relief and healing.

The SCENAR impulse is carried via efferent nerve fibers. When the SCENAR interprets this response via computer modulation, the results in its next impulse are being modified accordingly, which further provides the information back to the brain to either amplify or dampen the pathological signals initiating pain, ultimately leading to homeostasis. Thus the SCENAR operates on the very principle of being able to self-generate physiologically determined electrical pulses. These pulse patterns can be constantly modulated in response to signals that the SCENAR device receives. These input signals are acquired by monitoring the activity within the client’s own body via placement of the device on the client’s skin. This device-body-device interaction is called biological feedback (biofeedback).

The aim of the biofeedback loop generated by SCENAR is to help activate the potential resources within the body for self-healing 1, 2,12 to normalize metabolism, to exert analgesic and antiphlogistic impact, to improve the blood circulation, to decrease edema, etc., 2,6,7,8. Scenar training protocols include rating of pain, measurement of range of movement and testing of movement related to functional impairment. Almost every day we are seeing thrilling advances in the study and capability of the SCENAR. Unlike modern, medical therapies, it is not concerned with curing a given organ or system. It focuses on assisting the bodies stressed functions as a whole allowing the body to re-establish its own unique balance within all its functions. This in turn allows the body system to be “at ease” with each other and not in conflict or at ‘dis-ease’. It is not uncommon, when dealing with a particular stressor, to notice that other, unlooked for positive effects have occurred within a client as full stress/pain reduction progresses. Consequently, more and more medical practitioners and physicians are becoming openly enthusiastic in their support for this new technology.

The SCENAR device can provide a unique non-invasive opportunity of stress reduction across all of the multiple disciplines that comprise of today’s conventional medicine benefiting from faster recovery times, versatility and no concurrent medication interactions providing a therapeutic effect for stress reduction in acute, chronic and post- surgical/operative pain, that activates the natural defenses of the body through stimulation of reflective zones and acupuncture points on the skin surface 3,4,5. For those individuals who do not have a medical education, SCENAR devices serve as an all-around general purpose device for relief and management of acute and chronic pain. The SCENAR has been cleared for marketing by the FDA for delivering general non-invasive training via human skin areas for relief and management of chronic and acute pain as, adjunctive treatment in the management of post-surgical and post-traumatic pain. Class 2 device/Regulation no. 882.5050/882.5890

The development of SCENAR devices and protocols is closely connected with RITM OKB ZAO, established in 1980. RITM OKB ZAO participated in the Russian National Program of space research during the 80’s The main task of RITM OKB ZAO was the development of methods and means of correction of the psycho physiological state of healthy individuals (astronauts, pilots, elite athletes, etc.)

Observed clinical effects of SCENAR protocols:

Immediate pain relief. In autonomic responses from the client, the sympathetic CNS might include; perspiration, heart beat and slight blood pressure increases, clients may feel warm. When the parasympathetic responds generally after 10 to15 min. of Scenar training most clients become relaxed, heartbeat slightly decreases, and blood pressure normalizes. With Post SCENAR training the majority of client’s report of having prolonged deep sleeps, sometimes the first time in years. We find range of motion increases due to muscular relaxation, and increases of microcirculation directly under the SCENAR electrode; (one can see the erythema after a few minutes of application), clients may have a feeling of well-being, lightness, relaxed, sleepy, but not tired these are all observed clinical effects of Scenar protocols.

  1. Gorodetskyi I G, Gorodnichenko A I, Tursin P S, Reshetnyak V K, Uskov, O N: Non-invasive interactive Neurostimulation in the post-operative recovery of patients with a trochanteric fracture of the femur. J Bone Joint Surg [Br]2007;89-B:1488-94.
  2. G. Gorodetskyi et al, The effects of non-invasive, interactive Neurostimulation on pain and edema during post-surgical rehabilitation following internal fixation of unstable bi-malleolar ankle fractures, Presented as a poster by Dr James Dillard at the IASP 2008, Glasgow, Scotland. Accepted for publication Dec 2009, Journal of Foot and Ankle Surgery
  3. Lee KH, Chung JM, Willis WD. Inhibition of primate spinothalamic tract cells by TENS. J Neurosurg. 1985; 62: 276-287
  4. Linda S. Chesterton, Nadine E. Foster, Christine C. Wright, G. David Baxter and Panos Barlas
    Effects of TENS frequency, intensity and stimulation site parameter manipulation on pressure pain thresholds in healthy human subjects
    Pain, Volume 106, Issues 1-2, November 2003, Pages 73-80
  5. Garrison DW, Foreman RD: Effects of prolonged transcutaneous electrical nerve stimulation (TENS) and variation of stimulation variables on dorsal horn cell activity, Eur J Phys Med Rehabil 6:87-94, 1997
  6. Reilly JP, Applied Bioelectricity: From Electrical Stimulation to Electropathology, 1998 Springer-Verlag NY. pg 130 and 233
  7. Christie Q. Huang, Robert K. Shepherd Reduction in excitability of the auditory nerve following electrical stimulation at high stimulus rates: Varying Effects of electrode surface area Hearing Research 146 (2000) 57-71
  8. Pyne-Geithman G, Clark J F, InterX elicits significantly greater physiological response than TENS: Lymphocyte metabolism and Cytokine production. Presented as a poster at IASP 2010, Montreal, Canada. Aug. 29th 2010.
  9. Somers D, Clemente F R, TENS for the management of neuropathic pain: The effects of frequency and electrode position on prevention of allodynia in a rat model of CRPS type II, Phys Ther, Vol. 86, no.5, 2006: pg 698-709
  10. Han J S, Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. Trends in Neurosciences, Vol. 26, No.1, January 2003
  11. Hamza, M.A. et al. (1999) Effect of the frequency of transcutaneous electrical nerve stimulation on the postoperative opioid analgesic requirement and recovery profile. Anesthesiology 91, 1232–1238
  12. Robert O. Becker, M.D. and Gary Selden, The Body Electric, Electromagnetism and the Foundation of Life.

References

Lishnevski SA (2002). Biocontrollable electrostimulation of clinics in nervous diseases. Likarska Sprava;(7):68-70. Kiev, Ukraine.

Maklesova et al 2002. Influence of SCENAR therapy on GABA content, antioxidant and epileptic activities. European Neuropsychopharmacology: 12(3); 426.

Maljushko OA, et al. SCENAR AND ANTIHOMOTOXIC MEDICATIONS IN THE PREMENSTRUAL SYNDROM THERAPY. SCENAR-therapy and SCENAR-expertise. Issue 9-10, Taganrog. Collection of Articles, Unpublished study.

Moiseev, SV. SCENAR Technology and Sports Medicine publication, translation from Russian to English, Unpublished study.

Tarakanov AV et al (2007). SCENAR in therapy of chronic insomnia and neurocirculatory asthenia in emergency doctors. Translated from Non-drug Medicine journal. Academic and research journal. №1 – 2007 – pp.37-41.

Tarakanov et al (2009). The dependence of the oxidative stress on the number of strokes in early postinfarction angina pectoris. Skoraya Meditsinskaya Pomosch (Emergency) journal.№ 2 – pp. 62-65.

Tarakanov AV, et al (2005). Multifactor mechanism of SCENAR-analgesia. Reflexology Journal, Issue No: 3 (7), Moscow, Russia.

Timiras, P. (1994). Physiological basis of aging and geriatrics, 2nd ed. CRC Press, Boca Raton.

Trembach GA, et al. Using the Method of Non-Specific Stress-Resistance Improvement for Treating the Irritable Bowel Syndrome. Russian Centre of Functional Surgical Gastroenterology, Krasnodar; RITM OKB ZAO, Taganrog. Unpublished study.

Tsimmerman IaS, Kochurova IA, Vladimirskii EV (2006). Physiotherapy of gastric ulcer and duodenal ulcer. Klinicheskaia Medicina, 7/2003, Perm, 2006, Russia

S. A. Lishnevski (2002). Biocontrollable electrostimulation in clinics of nervous diseases. Likarska Sprava 2002;(7):68-70, Kiev, Ukraine

U.U. Starovoinov, U.I. Perfiliev, A.A. Krammarenko (2007). Book General SCENAR Therapy for personal and home use.

Zaidiner B et al, (2006). Analgesia with device for sensory restoration. Support Care Cancer 14: Pp 654.

Zaidiner B et al, (2007). SCENAR-technology for chemotherapy-induced neurotoxicity. Support Care Cancer 15: Pp753.

Tarakanov AV et al (2009). Effect of Artrofoon and SCENAR Therapy on Parameters of LPO and Antioxidant System of the Blood in Patients with Peritonitis in Postoperative Period. Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 148, Suppl. 1, pp. 136-139.

Chernov, JN et al (2004). Advantages of SCENAR therapy in treating chronic adnexitis. SCENAR-therapy and SCENAR-expertise. Issue 9-10, Taganrog. Collection of Articles, Unpublished study.

Coleman, S. The Combination Of SCENAR And Activity Based Program For The Rehabilitation Of Individuals Affected By Paralysis. Unpublished study.

Juully Lyons, Overview of Scenar therapy and its application to physiotherapy practice. Unpublished article

Klimova LV et al. SCENAR-therapy effect on the state of the blood plasma redox balance in patients with organ ischemic injury. Emergency Department, Rostov State Medical University (Rostov-on-Don) Clinical Trials Department, RITM OKB ZAO (Taganrog) Emergency Hospital №2 (Rostov-on-Don). Unpublished study.

Kulizhskiy BP, et al. SCENAR-therapy in Ischemic Stroke Rehabilitation, Collection of Articles. Unpublished study.

Lipkova, M. Three Case studies: Treatment Of Alopecia, Burns and Psoriasis In Bioregeneration SCENAR-Centre Slovakia. Unpublished study.

The influence of SCENAR therapy on the Nervous System and the Demonstration of Oxidative Stress before Alcoholic Addiction, Vinukov V.V., Milutina N.P., Ananyan A.A., Greenburn Y.Z., Danilov M.O., Ovsyanikov M.V., Panchenko L.F. Department of Biochemistry and Microbiology of the Southern University Federation, Rostov-na-Don, National Learning Center of Narcology MZ Russain Federation, Moscow, Bureau of research clinician ZAO OKB “Ritm”, Taganrog.

Disclaimer:

The purpose of this information is to describe the technology, use, safety and effectiveness of SCENAR therapy and should not be considered complete or take the place of a consultation with a physician or competent healthcare professional for medical diagnosis and or treatment/training. While every effort has been made to ensure the accuracy of information SCENAR-USA who gathered this information disclaims any responsibility for any results of the application. No information is intended or should be used as a substitute for professional medical advice. The information contained is based on research and anecdotal experience carried out by Russian scientists and the founders of SCENAR therapy, Y. Gorfinkel, A. Revenko, and Y. Grinberg et al.